Business Numinus to enter US psychedelics market via $26.2M Novamind acquisition The transaction is expected to close around June Natalia Buendia CalvilloApril 12, 2022
Medical and Pharmaceutical Psilocybin temporarily disrupts stages of the sleep cycle : study But whether or not the disruption helps with the substance's antidepressant properties still needs further research Natalia Buendia CalvilloApril 11, 2022
Legalization Georgia advances bill to create psychedelic study group focused on Veterans’ mental health Lawmakers note that current therapeutic trials for substance use issues exclude people with a history of substance abuse Natalia Buendia CalvilloMarch 29, 2022
News Therapists’ personal experience important for patients undergoing psilocybin-assisted therapy: study Previous experience was rated more important than shared symptoms, gender or ethnicity Natalia Buendia CalvilloMarch 28, 2022
Business Universal Ibogaine hires ex-Canopy research director ahead of clinical trial application The firm owns rights to a treatment protocol used at a popular clinic in Cancun, Mexico Natalia Buendia CalvilloMarch 23, 2022
Business Numinus gets new biosecurity licence to expand psilocybin research CEO Payton Nyquvest says the authorization moves his firm closer to developing medicines at scale to support psychedelic-assisted therapy Nick LabaMarch 14, 2022
Psychedelics Psilocybin safer to take with psychiatric medications than MDMA, researchers say Mixing MDMA with heavier antidepressants can be fatal Natalia Buendia CalvilloMarch 10, 2022
Business Numinus approved to study ayahuasca and San Pedro in Canada Used in sacred traditions for centuries, the firm says research will bring their medicinal benefits to a larger audience Natalia Buendia CalvilloMarch 9, 2022
News Only difference between LSD and synthetic psilocybin experience is duration, researchers say But there are some physiological differences between the two Natalia Buendia CalvilloMarch 2, 2022
News Psilocybin therapy for major depression can relieve symptoms for a year: study The long-term benefits contrast with the more temporary effects of conventional antidepressants Natalia Buendia CalvilloFebruary 18, 2022